Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

CellSource

セルソース

4880 · TSE · Pharmaceutical · 1 article

Financials Consolidated

Revenue¥3.71bnConsolidated · FY10/25

Operating profit¥167mConsolidated · FY10/25

Net profit¥10.7mConsolidated · FY10/25

Dividend per share¥5.00FY10/25

Performance over time

People & pay

Employees, whole group148 peopleFY10/25

Employees, parent company (non-consolidated)148 peopleFY10/25

Average salary¥6.63mFY10/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOp. profitNet profit (attributable)EPSDividendOp. cash flow
FY10/25¥3.71bn¥167m¥10.7m¥0.54¥5.00¥333m
FY10/24————¥5.00—
FY10/23————¥20.00—

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XHWF · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4880

Tokyo Brief coverage

  1. CellSource cuts its way to interim profit, but keeps full-year operating loss forecast

    CellSource turned a softer top line into a better interim profit picture. Consolidated revenue for the six months to April slipped 2.5% to JPY 1,775m, but SG&A fell 8.5% and operating profit climbed to JPY 125m from JPY 17m, even as combined blood- and adipose-derived processing cases edged down to 10,114 from 10,303. Management still kept its full-year forecast for a JPY 170m operating loss, saying the year remains one of strategic investment rather than tidy recovery.

All articles loaded · 1 shown

5% holders

Latest disclosed holders and exits below 5%.

1 holder · data through

5% holders
HolderStakeChangePurposeFiling
山川 雅之10.95% own · 45.71% group of 2−0.07 ppStable shareholderHeld as a stable shareholderMachine translated
Original (Japanese)安定株主として保有
Filed  — filing S100Z2FY

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

4 fiscal years · data through

Sale proceeds
¥80.0mFY10/23
¥66.5mFY10/24

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Oct 2025No listed strategic holdings reported————Filed 
Show 3 more fiscal years (4 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Oct 2024———1¥66.5mFiled  — filing S100V5YX
31 Oct 20231¥32.9m—1¥80mFiled  — filing S100SOC8
31 Oct 2022No listed strategic holdings reported————Filed 

Fund positioning

Current holdings disclosed by tracked funds.

14 funds · data through

Held by 14 tracked funds; largest weight 0.01%. Holdings as of 30 Oct 2026–20 Nov 2026.

Show 4 more funds (14 total)